{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007650","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.489766+00:00","generated_at":"2026-05-21T09:11:31.863172+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Scholar Rock Q1 net loss $74.7M; BLA priority review set for Sept 22, 2025; cash to 2027","bullets":["Net loss $74.7M ($0.67 per share) vs $56.9M in Q1 2024; no revenue.","Cash, equivalents, securities $364.4M as of March 31, 2025; expected to fund into 2027.","FDA accepted BLA for apitegromab with priority review; PDUFA date Sept 22, 2025.","Topline results from Phase 2 EMBRAZE obesity trial expected June 2025.","Leadership: David Hallal CEO; Akshay Vaishnaw President R&D; Keith Woods COO; Vikas Sinha CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007650","json":"https://secwatch.observer/filing/0001558370-25-007650.json","markdown":"https://secwatch.observer/filing/0001558370-25-007650.md","text":"https://secwatch.observer/filing/0001558370-25-007650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/0001558370-25-007650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:11:31.863172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}